NBW Capital LLC trimmed its stake in shares of STERIS plc (NYSE:STE - Free Report) by 3.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,640 shares of the medical equipment provider's stock after selling 1,126 shares during the quarter. NBW Capital LLC's holdings in STERIS were worth $5,887,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its position in STERIS by 171.2% during the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider's stock worth $191,370,000 after buying an additional 529,308 shares during the last quarter. Boston Trust Walden Corp increased its position in shares of STERIS by 400.4% during the fourth quarter. Boston Trust Walden Corp now owns 224,741 shares of the medical equipment provider's stock valued at $46,198,000 after purchasing an additional 179,829 shares during the period. Swedbank AB bought a new position in shares of STERIS during the 3rd quarter worth about $28,251,000. Benjamin Edwards Inc. lifted its position in shares of STERIS by 2,123.2% during the 3rd quarter. Benjamin Edwards Inc. now owns 113,672 shares of the medical equipment provider's stock worth $27,574,000 after buying an additional 108,559 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in shares of STERIS by 9.5% in the 3rd quarter. Principal Financial Group Inc. now owns 1,114,224 shares of the medical equipment provider's stock valued at $270,230,000 after purchasing an additional 96,336 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.
STERIS Price Performance
Shares of STE stock traded up $0.77 during trading hours on Friday, reaching $233.02. The stock had a trading volume of 667,286 shares, compared to its average volume of 519,485. The firm has a market capitalization of $22.89 billion, a PE ratio of 49.47 and a beta of 0.92. STERIS plc has a 12 month low of $197.82 and a 12 month high of $248.24. The stock's fifty day simple moving average is $216.46 and its 200 day simple moving average is $222.86. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32.
STERIS (NYSE:STE - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. On average, equities research analysts predict that STERIS plc will post 9.08 EPS for the current year.
STERIS Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date is Thursday, February 20th. STERIS's dividend payout ratio (DPR) is presently 48.41%.
Wall Street Analysts Forecast Growth
STE has been the topic of several recent research reports. Piper Sandler raised their price target on STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Needham & Company LLC reissued a "hold" rating on shares of STERIS in a research report on Friday, November 8th. JMP Securities reissued a "market outperform" rating and set a $265.00 price target on shares of STERIS in a research report on Thursday, February 6th. Finally, Stephens reiterated an "overweight" rating and issued a $240.00 target price on shares of STERIS in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $258.75.
Check Out Our Latest Analysis on STE
STERIS Company Profile
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
